Lewy Body Dementia Psychosis
Neurology
2
Pipeline Programs
1
Companies
2
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
1
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Acadia PharmaceuticalsSAN DIEGO, CA
2 programs1
1
ACP-204Phase 31 trial
ACP-204Phase 21 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2025
2026
2027
2028
2029
Acadia PharmaceuticalsACP-204
Acadia PharmaceuticalsACP-204
Clinical Trials (2)
Total enrollment: 306 patients across 2 trials
Phase 3, Open Label Extension Study of ACP-204 in Lewy Body Dementia Psychosis
Start: Nov 2025Est. completion: Mar 2029126 patients
Phase 3Enrolling By Invitation
Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis
Start: Aug 2025Est. completion: Mar 2028180 patients
Phase 2Recruiting
Related Jobs in Neurology
Director, Distribution & Services
Xenon Pharmaceuticals
Remote
10h ago
Senior Medical Science Liaison (NYC Tri-State)
Xenon Pharmaceuticals
Remote
10h ago
$208K - $234K/yr
Director of Medical Affairs
CoMind
Miami, FL
10h ago
Director of Finance
CoMind
London, UK
10h ago
Electronics Engineering Manager
CoMind
London, UK
10h ago
Director of Information Technology
Zavation Medical Products
10h ago
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 306 patients
1 companies competing in this space